BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31435529)

  • 21. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway.
    Qiao Y; Wang B; Yan Y; Niu L
    Environ Toxicol; 2022 Oct; 37(10):2398-2411. PubMed ID: 35730485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential roles of lncRNA TINCR in triple negative breast cancer.
    Azman AA; Siok-Fong C; Rajab NF; Md Zin RR; Ahmad Daud NN; Mohamad Hanif EA
    Mol Biol Rep; 2023 Sep; 50(9):7909-7917. PubMed ID: 37442895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting.
    Talukdar S; Bhoopathi P; Emdad L; Das S; Sarkar D; Fisher PB
    Adv Cancer Res; 2019; 141():43-84. PubMed ID: 30691685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.
    Zheng S; Yang L; Zou Y; Liang JY; Liu P; Gao G; Yang A; Tang H; Xie X
    J Hematol Oncol; 2020 Mar; 13(1):17. PubMed ID: 32138762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remodeling the ECM: Implications for Metastasis and Tumor Dormancy.
    Di Martino JS; Akhter T; Bravo-Cordero JJ
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular dormancy in minimal residual disease following targeted therapy.
    Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
    Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression predicts dormant metastatic breast cancer cell phenotype.
    Ren Q; Khoo WH; Corr AP; Phan TG; Croucher PI; Stewart SA
    Breast Cancer Res; 2022 Jan; 24(1):10. PubMed ID: 35093137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
    Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
    Shimizu H; Takeishi S; Nakatsumi H; Nakayama KI
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel long non-coding RNA MIR4500HG003 promotes tumor metastasis through miR-483-3p-MMP9 axis in triple-negative breast cancer.
    Lin WD; Chang CH; Pan JK; Lin FC; Chen YC; Chen YJ; Wang PS; Hong WQ; Chen SY; Lin CH; Kuo YL; Chung WP; Cheng HC; Hsiao M; Yang CN; Lu PJ
    Cell Death Dis; 2024 May; 15(5):310. PubMed ID: 38697967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dormancy in Breast Cancer, the Role of Autophagy, lncRNAs, miRNAs and Exosomes.
    Jahangiri L; Ishola T
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities.
    Ramamoorthi G; Kodumudi K; Gallen C; Zachariah NN; Basu A; Albert G; Beyer A; Snyder C; Wiener D; Costa RLB; Czerniecki BJ
    Semin Cancer Biol; 2022 Jan; 78():78-89. PubMed ID: 33626407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LncRNA T376626 is a promising serum biomarker and promotes proliferation, migration, and invasion via binding to LAMC2 in triple-negative breast cancer.
    He Y; Xiao B; Lei T; Xuan J; Zhu Y; Kuang Z; Liu J; He J; Li L; Sun Z
    Gene; 2023 Apr; 860():147227. PubMed ID: 36709879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease.
    Siddappa CM; Watson MA; Pillai SG; Trinkaus K; Fleming T; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):45-56. PubMed ID: 23129172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities.
    De Angelis ML; Francescangeli F; Zeuner A
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31619007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis.
    Hu J; Huang H; Xi Z; Ma S; Ming J; Dong F; Guo H; Zhang H; Zhao E; Yao G; Yang L; Zhang F; Zheng W; Chen H; Huang T; Li L
    Cell Death Dis; 2022 Sep; 13(9):800. PubMed ID: 36123344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings.
    Shor RE; Dai J; Lee SY; Pisarsky L; Matei I; Lucotti S; Lyden D; Bissell MJ; Ghajar CM
    Mol Oncol; 2022 Jan; 16(1):130-147. PubMed ID: 34058066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
    Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
    Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.
    Augoff K; McCue B; Plow EF; Sossey-Alaoui K
    Mol Cancer; 2012 Jan; 11():5. PubMed ID: 22289355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.